EBS
Emergent Biosolutions Inc
6.80$
+0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.8% | 38.8% | 53.1% | 125.7% | 44.1% | 29.9% | 47.6% | 59.2% | 44.1% | 68.7% | 56.7% | 41.4% | 50.6% | |
| 34.2% | 61.2% | 46.9% | -25.7% | 55.9% | 70.1% | 52.4% | 40.8% | 55.9% | 31.3% | 43.3% | 58.6% | 49.4% | |
| 5.7% | 10.6% | 5.0% | 12.8% | 4.7% | 4.7% | 6.8% | 9.2% | 5.8% | 8.1% | 6.7% | 3.9% | 5.9% | |
| 31.8% | 32.4% | 28.2% | 33.7% | 26.1% | 31.2% | 23.6% | 31.0% | 16.8% | 34.4% | 29.9% | 19.0% | 23.5% | |
| 123.7% | 77.0% | 33.6% | 54.2% | 33.9% | 75.0% | 30.6% | 40.5% | 22.6% | 42.5% | 36.6% | 112.0% | 56.5% | |
| -89.5% | -15.8% | 13.2% | -79.9% | 22.0% | -4.9% | 21.9% | 0.4% | 33.2% | -11.2% | 6.7% | -53.4% | -7.1% | |
| 7.3% | 8.0% | 8.1% | 9.3% | 2.8% | 7.6% | 6.6% | 10.4% | 6.6% | 9.9% | 7.0% | 4.3% | 6.6% | |
| -98.3% | -19.7% | 4.0% | -105.9% | 48.5% | -14.2% | 41.7% | -11.9% | 24.9% | -34.1% | 8.6% | -71.0% | -19.0% | |
| -0.9% | -1.8% | 1.0% | 5.2% | 9.4% | 1.9% | 11.1% | -3.4% | 2.8% | 2.6% | 4.2% | 5.9% | 4.0% | |
| -97.4% | -17.9% | 3.0% | -111.2% | 39.1% | -16.1% | 30.6% | -8.5% | 22.2% | -36.7% | 4.4% | -76.9% | -23.0% | |
| 8.6% | -4.9% | 21.1% | -51.6% | 33.3% | 10.8% | 60.0% | 15.5% | 41.8% | -8.4% | 31.1% | -66.7% | -3.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.